NetImpact: Scientists Investigate Using MDS200 to Detect Mad Cow Disease; Unit Tests With Blood Samples, Avoiding Slaughter Of H

NetImpact: Scientists Investigate Using MDS200 to Detect Mad Cow Disease; Unit
Tests With Blood Samples, Avoiding Slaughter Of Herds 


LAS VEGAS, Feb. 9  /PRNewswire-FirstCall/ -- NetImpact Holdings, Inc. (OTC Pink
Sheets: NTHD) today announced that scientists, including biochemists and
bioengineers, are investigating the possibility of using NetImpact's MDS200 to
detect Mad Cow disease. Scientists will place samples of the cow's blood or
neural tissue into the MDS200 to further develop and test the system to identify
the disease. Using cow's blood avoids slaughtering the animal to access brain
stem tissue or slaughtering herds of cows to stop the spread of the disease.

The brain stem tissue test produces accurate results in about one week.

NetImpact expects the MDS200 test to produce accurate results in a matter of
hours.

NetImpact anticipates positive reports from the scientific team. The Company
plans to move their lab in a box to market without delay and is pursuing
partnerships with otherfirms and investment capital groups in the U.S., Canada,
England, Japan and Australia.

The MDS200 lab in a box is a breakthrough technology for disease detection.
Currently used on solids, gases and fluids, it is capable of automatic
preparation and testing of difficult and dirty samples containing cell, protein,
nucleic acid and chemical analytes. About the size of a small suitcase, the
MDS200 is a rugged portable laboratory designed for use in remote areas with
non-existent or scarce laboratory facilities and readily carried from location
to location. Test results are displayed on the unit's LED and can be sent via
satellite or dial up connections. Once a sample has been placed in the lab in a
box the processing is spontaneous. Operating an MDS200 does not require a
trained lab technician.

About NetImpact Holdings, Inc.

NetImpact Holdings, Inc. is a technology-to-market company focusing on the
installation, restructuring and management of global healthcare and medical
delivery systems. Through acquisitions and extensive access to
international/U.S. distribution networks, NetImpact specializes in presenting
technology that will assist in the improvement of productivity, applications
development, and technology transfer in developing countries. The Company's
NetCare Division, Medical and Diagnostic Devices Division, and Neurowave
Division are moving their technologies, products and services to an awaiting
market.

Safe Harbor Statement

The statements in this release that are not historical facts are forward-
looking statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. NetImpact Holdings,
Inc. intends that such forward-looking statements be subject to the safe harbors
created thereby. These forward-looking statements include predictions, estimates
and other statements that involve a number of risks and uncertainties any, or
all, of which could cause actual results to differ materially from any future
performance suggested herein. While this outlook represents NetImpact Holdings,
Inc.'s current judgment on the future direction of the business, such risks and
uncertainties may individually, or mutually, impact the matters herein
described, including but not limited to product acceptance, the economy,
competition, governmental actions, results of litigation, technological and/or
other factors, which are outside the control of NetImpact Holdings, Inc. as well
as those risks and uncertainties detailed in the Company's Security and Exchange
Commission filings.

   CONTACT
   Jerry Jennings
   Emerson Gerard Associates
   561-881-7318
   

DATASOURCE: NetImpact Holdings, Inc.



CONTACT:  Jerry Jennings, Emerson Gerard Associates, [phone], or

, for NetImpact



Web site:  http://www.netimpact.com/

Copyright